Skip Navigation

CCPM Educational Outreach

  • CCPM Tumor Board meeting

  • The Center for Cancer Precision Medicine's Tumor Board is a monthly meeting in which we discuss one or two interesting cases on a topic in genomics and precision medicine.

    Email CCPM_ResearchOps@dfci.harvard.edu to be added to the distribution list for this meeting.

    Some previous Tumor Boards have featured:

    • Geoffrey Oxnard, MD
      Mining somatic genotyping for germline risk alleles: germline EGFR mutations and familial lung cancer
    • David Barbie, MD
      A functional precision approach to developing combination cancer immunotherapies
    • Brian Crompton, MD/David Shulman, MD
      Adapting liquid biopsy assays to pediatric solid tumors: a first step in non-invasive precision medicine for children
    • Heather Parsons, MD, MPH
      Precision medicine in early-stage breast cancer
    • Bruce Johnson, MD
      EGFR mutations in lung cancer
    • Eliezer Van Allen, MD/Amin Nassar, MD
      Enrichment of FGFR3-TACC3 fusions in bladder cancer patients who are young, Asian, or have never smoked
    • Eliezer Van Allen, MD/Amin Nassar, MD
      A combined clinical and genomic model for PD1/PDL1 blockade efficacy in advanced urothelial carcinomas
    • Pasi Jänne, MD, PhD/Ian Krop, MD, PhD
      HER2 discussion/HER2 with both TKIs and ADCs/trials ongoing for HER2 mutant NSCLC patients
    • Nikhil Wagle, MD
      MTOR pathway mutations in cancer
    • Nikhil Wagle, MD
      HER2 mutations and amplifications in cancer
    • Nikhil Wagle, MD
      IDH1/2 mutations in hematologic malignancies and solid tumors
    • Nikhil Wagle, MD/Geoffrey Oxnard, MD/Pasi Jänne, MD
      EGFR T790M mutations in lung cancer: resistance and risk
    • Katherine Janeway, MD
      Pediatric oncology: a case of acute lymphoblastic leukemia and a case of hepatocellular carcinoma highlighting the complexity of data analysis and clinical interpretation
    • Nikhil Wagle, MD
      Targeting MET in cancer
    • Nikhil Wagle, MD
      Comprehensive genomic assessment for precision medicine: metastatic breast cancer
    • Marios Giannakis, MD, PhD
      Novel targeted and immunotherapeutic approaches in colorectal cancer
    • Eliezer Van Allen, MD
      Prostate cancer and somatic-germline alterations in DNA repair
    • Elizabeth Stover, MD, PhD
      PARP inhibitors and precision medicine in ovarian cancer
    • Keith Ligon, MD, PhD
      CNS malignancies
    • Brian Wolpin, MD, MPH/Andrew Aguirre, MD, PhD
      Pancreatic cancer
    • Nikhil Wagle, MD
      Precision medicine in metastatic breast cancer
    • Eliezer Van Allen, MD/Toni Choueiri, MD/Joaquim Bellmunt, MD, PhD
      Emerging opportunities for precision medicine in urinary cancers
    • Nikhil Wagle, MD
      Precision medicine in metastatic breast cancer
    • Benjamin Izar, MD, PhD
      Dissecting treatment resistance in melanoma by single-cell profiling approaches
    • Stephen Hodi, MD
      Personalized approaches to immune therapy
    • Andrew Aguirre, MD, PhD
      Precision medicine in pancreatic cancer
    • Coleman Lindsley, MD, PhD
      Genomic profiling in inherited and acquired myeloid malignancies
    • Marios Giannakis, MD, PhD/Lynette Scholl, MD/Jonathan Nowak, MD, PhD
      Immune Checkpoint Inhibitors
    • Rameen Beroukhim, MD, PhD
      Missing links—features of oncogenic rearrangements
    • Margaret Shipp, MD
      Targetable genetic bases of immune evasion in lymphoma